102515CRISPR in the Wild: demonstrating model-driven epigenome editing in cancerClosedCollaborative R&DInnovate UKEpigenome editing provides an opportunity to reverse aberrant epigenetic drivers of diseases such as cancer where epigenetic change drives tumour evolution and determines treatment success. Adapting CRISPR/Cas9 genome editing to the clinic requires the integration of large, heterogeneous biological data sets into a unified in silico cellular model suitable for vector design and analysis. We propose to integrate genome, epigenome, and transcriptome sequencing for designing epigenome modifying CRISPR (EpiCRISPR) vectors. Our software platform will map epigenetic changes associated with disease states and design EpiCRISPR libraries targeting gene regulatory elements associated with an altered epigenetic landscape to generate novel epigenome editing treatment approaches. We will utilise the drug-resistance in ovarian cancer as a test case, where clinically relevant genomic and epigenomic datasets have already been generated and there is a clinical need to improve patient outcome by overcoming drug resistance. We anticipate a tool of this caliber will allow for unparalleled insight into the function of cellular mechanisms and thus hugely impact translational omics research.